Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Bianchini · SciRah

Researcher profile · Semantic Scholar

D. Bianchini

Share profile

D. Bianchini — researcher profile on SciRah

h-index: 42
Works: 135
Citations: 14K

Most-cited papers

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo, S. Carreira, S. Sandhu, S. Miranda +47 more
2015New England Journal of Medicine2,015 citations Open access
Semantic Scholar
Genomic correlates of clinical outcome in advanced prostate cancer
W. Abida, J. Cyrta, G. Heller, D. Prandi +39 more
2019Proceedings of the National Academy of Sciences of the United States of America1,265 citations Open access
Semantic Scholar
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
J. Mateo, N. Porta, D. Bianchini, U. McGovern +37 more
2019The Lancet Oncology570 citations Open access
Semantic Scholar
Plasma AR and abiraterone-resistant prostate cancer
A. Romanel, Delila Gasi Tandefelt, V. Conteduca, A. Jayaram +19 more
2015Science Translational Medicine455 citations Open access
Semantic Scholar
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
A. Paschalis, Beshara Sheehan, R. Riisnaes, D. Rodrigues +17 more
2019European Urology412 citations Open access
Semantic Scholar
Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
J. Goodall, J. Mateo, W. Yuan, H. Mossop +30 more
2017Cancer Discovery378 citations Open access
Semantic Scholar
Genomics of lethal prostate cancer at diagnosis and castration resistance
J. Mateo, G. Seed, C. Bertan, P. Rescigno +31 more
2019Journal of Clinical Investigation270 citations Open access
Semantic Scholar
PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
R. Ferraldeschi, Daniel Nava Rodrigues, R. Riisnaes, S. Miranda +20 more
2015European Urology258 citations Open access
Semantic Scholar
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
D. Bianchini, D. Lorente, A. Rodríguez-Vida, A. Omlin +6 more
2014European Journal of Cancer210 citations
Semantic Scholar
Visceral disease in castration-resistant prostate cancer
C. Pezaro, A. Omlin, D. Lorente, D. Rodrigues +9 more
2013European Urology205 citations Open access
Semantic Scholar
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
D. Lorente, J. Mateo, A. Templeton, Z. Zafeiriou +7 more
2015Annals of Oncology203 citations Open access
Semantic Scholar
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
Daniel Nava Rodrigues, P. Rescigno, David Liu, W. Yuan +48 more
2018Journal of Clinical Investigation195 citations Open access
Semantic Scholar
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
C. Pezaro, A. Omlin, A. Altavilla, D. Lorente +6 more
2014European Urology156 citations Open access
Semantic Scholar
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
D. Lorente, D. Olmos, J. Mateo, D. Bianchini +14 more
2016European Urology137 citations Open access
Semantic Scholar
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
S. Carreira, N. Porta, Sara Arce-Gallego, G. Seed +23 more
2021Cancer Discovery129 citations Open access
Semantic Scholar
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
G. Boysen, D. Rodrigues, P. Rescigno, G. Seed +29 more
2018Clinical Cancer Research121 citations Open access
Semantic Scholar
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
N. Mehra, D. Dolling, S. Sumanasuriya, R. Christova +16 more
2018European Urology112 citations Open access
Semantic Scholar
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
A. Neeb, Nicolás Herranz, Sara Arce-Gallego, S. Miranda +38 more
2020European Urology105 citations Open access
Semantic Scholar
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
S. Schmid, A. Omlin, C. Higano, C. Sweeney +32 more
2020JAMA Network Open103 citations Open access
Semantic Scholar
Diffusion-weighted imaging as a treatment response biomarker evaluating bone metastases in prostate cancer: a pilot study
R. Pérez-López, J. Mateo, H. Mossop, M. Blackledge +15 more
2016Radiology101 citations Open access
Semantic Scholar
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
M. Lambros, G. Seed, S. Sumanasuriya, V. Gil +32 more
2018Clinical Cancer Research96 citations Open access
Semantic Scholar
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.
A. Omlin, C. Pezaro, D. Mukherji, Amy Mulick Cassidy +9 more
2013European Urology93 citations
Semantic Scholar
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts
D. Lorente, David Olmos, J. Mateo, D. Dolling +9 more
2018Annals of Oncology87 citations Open access
Semantic Scholar
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
Z. Zafeiriou, D. Bianchini, R. Chandler, P. Rescigno +17 more
2019European Urology76 citations Open access
Semantic Scholar
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
A. Sharp, J. Welti, M. Lambros, D. Dolling +31 more
2019European Urology72 citations Open access
Semantic Scholar
Characterizing CDK12-Mutated Prostate Cancers.
P. Rescigno, B. Gurel, Rita Pereira, M. Crespo +23 more
2020Clinical Cancer Research70 citations Open access
Semantic Scholar
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
M. Kolinsky, P. Rescigno, D. Bianchini, Z. Zafeiriou +26 more
2020Annals of Oncology68 citations Open access
Semantic Scholar
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
P. Rescigno, D. Lorente, D. Bianchini, R. Ferraldeschi +15 more
2016European Urology68 citations Open access
Semantic Scholar
Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer.
R. Pérez-López, D. Lorente, M. Blackledge, D. Collins +8 more
2016Radiology67 citations
Semantic Scholar
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents
M. Crespo, G. van Dalum, R. Ferraldeschi, Z. Zafeiriou +12 more
2015British Journal of Cancer59 citations Open access
Semantic Scholar
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
G. Seed, Nick Beije, W. Yuan, C. Bertan +32 more
2024Cancer Cell55 citations Open access
Semantic Scholar
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
S. Sumanasuriya, G. Seed, Harry Parr, R. Christova +27 more
2021European Urology55 citations Open access
Semantic Scholar
HER3 is an Actionable Target in Advanced Prostate Cancer.
V. Gil, S. Miranda, R. Riisnaes, B. Gurel +41 more
2021Cancer Research55 citations Open access
Semantic Scholar
TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.
J. Mateo, N. Porta, U. McGovern, T. Elliott +16 more
2019Journal of Clinical Oncology52 citations
Semantic Scholar
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
P. Rescigno, D. Lorente, D. Dolling, R. Ferraldeschi +14 more
2018European Urology Oncology41 citations Open access
Semantic Scholar
Is there an antiandrogen withdrawal syndrome with enzalutamide?
A. Rodríguez-Vida, D. Bianchini, M. van Hemelrijck, S. Hughes +7 more
2015BJU International36 citations
Semantic Scholar
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
D. Lorente, A. Omlin, Z. Zafeiriou, D. Nava-Rodrigues +16 more
2016Clinical Genitourinary Cancer34 citations Open access
Semantic Scholar
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone.
P. Ravi, J. Mateo, D. Lorente, Z. Zafeiriou +9 more
2014European Urology27 citations
Semantic Scholar
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.
D. Lorente, P. Ravi, N. Mehra, C. Pezaro +15 more
2016European Urology Focus24 citations Open access
Semantic Scholar
Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values
C. Messiou, David J. Collins, V. Morgan, D. Bianchini +2 more
2014Skeletal Radiology23 citations
Semantic Scholar
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.
P. Rescigno, D. Dolling, V. Conteduca, Mattia Rediti +23 more
2020European Urology Oncology22 citations Open access
Semantic Scholar
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital
D. Bianchini, D. Lorente, P. Rescigno, Z. Zafeiriou +19 more
2017Clinical Genitourinary Cancer19 citations Open access
Semantic Scholar
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
C. Massard, J. Mateo, Y. Loriot, C. Pezaro +10 more
2016Annals of Oncology17 citations Open access
Semantic Scholar
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
R. Lozano, D. Lorente, I. Aragón, N. Romero-Laorden +17 more
2021Cancers16 citations Open access
Semantic Scholar
Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer.
D. Lorente, D. Bianchini, A. Rodríguez-Vida, A. Omlin +6 more
2014European Journal of Cancer16 citations
Semantic Scholar
Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.
O. Caffo, M. Wissing, D. Bianchini, A. Bergman +14 more
2019Clinical Genitourinary Cancer14 citations
Semantic Scholar
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
C. Massard, J. Mateo, Y. Loriot, C. Pezaro +10 more
201713 citations Open access
Semantic Scholar
Myeloid-derived suppressor cells (MDSCs) in metastatic castration-resistant prostate cancer (CRPC) patients (PTS)
N. Mehra, G. Seed, M. Lambros, A. Sharp +15 more
201612 citations Open access
Semantic Scholar
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer.
C. Pezaro, A. Omlin, R. Pérez-López, D. Mukherji +8 more
2015Clinical Radiology9 citations Open access
Semantic Scholar
Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer
J. Mateo, S. Sandhu, S. Miranda, S. Carreira +30 more
20159 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. de Bono×47
Invite
J. de Bono — researcher profile on SciRah
J. Mateo×30
Invite
J. Mateo — researcher profile on SciRah
P. Rescigno×26
Invite
P. Rescigno — researcher profile on SciRah
S. Miranda×24
Invite
S. Miranda — researcher profile on SciRah

×23

Invite

S. Carreira — researcher profile on SciRah

Invite

N. Tunariu — researcher profile on SciRah

I. Figueiredo×22

Invite

I. Figueiredo — researcher profile on SciRah

Invite

G. Seed — researcher profile on SciRah

R. Riisnaes×20

Invite

R. Riisnaes — researcher profile on SciRah

Z. Zafeiriou×19

Invite

Z. Zafeiriou — researcher profile on SciRah

Invite

W. Yuan — researcher profile on SciRah

Invite

P. Flohr — researcher profile on SciRah